Posted by Michael Wonder on 12 Apr 2018
ICER posts draft scoping document on therapies for prevention of hereditary angioedema attacks
12 April 2018 - Document open to public comment until 2 May 2018; report expected to review lanadelumab (Shire), and C1 inhibitors Haegarda (CSL Behring), Cinryze (Shire), and Ruconest (Pharming).
The ICER has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of therapies for hereditary angioedema, a rare condition characterised by attacks of deep tissue swelling within the skin and/or mucosa. The scoping document will be open to public comment until 5pm ET on 2 May 2018.
The report will be subject to deliberation during a public meeting of the California Technology Assessment Forum, one of ICER's three independent evidence appraisal committees, in October of 2018.
